Haemonetics (NYSE: HAE) reported Q1 EPS of $0.36, $0.04 better than the analyst estimate of $0.32. Revenue for the quarter came in at $213.4 million versus the consensus estimate of $215.62 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.